Michael Duruisseaux

Trials

Studies that name Michael Duruisseaux as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:25 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT05200481 · Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

  Intergroupe Francophone de Cancerologie Thoracique · active not recruiting · Non Small Cell Lung Cancer, ALK Gene Mutation · principal investigator
• Ph2
  NCT04621188 · Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

  Intergroupe Francophone de Cancerologie Thoracique · active not recruiting · Non Small Cell Lung Cancer Metastatic · study chair
• Ph2
  NCT04111705 · Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

  Intergroupe Francophone de Cancerologie Thoracique · completed · Non Small Cell Lung Cancer Metastatic · study chair
• Ph2
  NCT04108026 · Immunotherapy in Patient With Poor General Condition

  Intergroupe Francophone de Cancerologie Thoracique · completed · Non-small Cell Lung Cancer Stage IV · study chair
• N/A
  NCT02727335 · Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements

  Intergroupe Francophone de Cancerologie Thoracique · completed · Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase Gene Mutation · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.